TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Equities research analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of TScan Therapeutics in a research note issued to investors on Wednesday, May 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.21) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.87) EPS, FY2028 earnings at ($0.80) EPS, FY2029 earnings at ($0.50) EPS and FY2030 earnings at ($0.07) EPS.
TCRX has been the subject of a number of other reports. Wall Street Zen downgraded TScan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Wedbush upped their target price on TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, TScan Therapeutics presently has a consensus rating of “Hold” and an average target price of $6.00.
TScan Therapeutics Stock Down 3.2%
Shares of TScan Therapeutics stock opened at $1.21 on Friday. The business’s fifty day moving average price is $1.11 and its two-hundred day moving average price is $1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.41 and a quick ratio of 8.41. The company has a market capitalization of $68.85 million, a P/E ratio of -1.26 and a beta of 1.06. TScan Therapeutics has a 1-year low of $0.88 and a 1-year high of $2.57.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative return on equity of 84.02% and a negative net margin of 1,360.61%.
Institutional Investors Weigh In On TScan Therapeutics
A number of institutional investors have recently added to or reduced their stakes in TCRX. Goldman Sachs Group Inc. lifted its position in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after purchasing an additional 9,676 shares during the period. JPMorgan Chase & Co. lifted its position in shares of TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after acquiring an additional 22,642 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $78,000. Qube Research & Technologies Ltd acquired a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $99,000. Finally, Jane Street Group LLC acquired a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $309,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.
About TScan Therapeutics
TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.
The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.
Further Reading
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
